Hydreight Technologies Inc. (TSXV:NURS)
Canada · Delayed Price · Currency is CAD | Market Cap | 167.99M -21.7% |
| Revenue (ttm) | 78.43M +324.3% |
| Net Income | 6.74M +478,192.1% |
| EPS | 0.13 +390,272.7% |
| Shares Out | 53.67M |
| PE Ratio | 24.30 |
| Forward PE | 6.66 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 147,832 |
| Open | 3.510 |
| Previous Close | 3.550 |
| Day's Range | 3.000 - 3.540 |
| 52-Week Range | 2.380 - 5.590 |
| Beta | 0.63 |
| Analysts | Buy |
| Price Target | 7.92 (+152.94%) |
| Est. Earnings | Nov 26, 2026 |
About Hydreight Technologies
Hydreight Technologies Inc. operates in the digital health technology sector in the United States. The company develops a proprietary telemedicine service that allows users to book confidential health and wellness, and/or medical services through a mobile application. It also provides consulting and advice in setting up health and wellness services, including assistance with finding experienced advisors in the areas of medical and privacy law, among others; medical liability insurance; pharmaceutical IV programs vetted by duly licensed pharmaci... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for NURS stock is "Buy." The 12-month stock price target is $7.92, which is an increase of 152.94% from the latest price.
News
Hydreight Technologies Transcript: Planet MicroCap Showcase: Toronto 2026
A modular, 50-state B2B healthcare platform is scaling rapidly: Q2 revenue was $28 million, up 420% YoY, and third-vertical licensees exceeded 11,000 by March-April 2026. Management sees peptide regulation and new treatments as growth catalysts through 2027 and beyond.
Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology
Milestone advances the technology behind Hydreight's strategic investment and previously announced U.S. distribution rights VANCOUVER, BC and LAS VEGAS, Oct. 8, 2026 /PRNewswire/ -- Hydreight Technolo...
Hydreight Technologies price target lowered to C$6.75 from C$8.25 at Canaccord
Canaccord lowered the firm’s price target on Hydreight Technologies (HYDTF) to C$6.75 from C$8.25 and keeps a Speculative Buy rating on the shares.
Hydreight Technologies Earnings Call Transcript: Q2 2026
Record Q2 revenue and profit were driven by broad-based growth across all business lines, with significant expansion in the direct-to-consumer platform and pharmacy partnerships. Full-year guidance is reaffirmed, with regulatory changes and strong demand expected to fuel further acceleration.
Hydreight Technologies Report: Q2 2026
Hydreight Technologies published a report on September 1, 2026 containing material business information for investors and shareholders.
Hydreight Technologies MD&A: Q2 2026
Hydreight Technologies filed a regulatory document on September 1, 2026 disclosing important business information.
Hydreight Technologies Earnings release: Q2 2026
Hydreight Technologies released its Q2 2026 earnings on September 1, 2026, summarizing the period's financial results.
Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million
Revenue increased 421% year-over-year as Hydreight delivered its strongest revenue quarter to date, with continued sequential growth in revenue and gross profit while maintaining strong profitability ...
Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A
VANCOUVER, BC and LAS VEGAS, Aug. 27, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a rapidly growing digital health platform ...
Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston
VANCOUVER, BC, Aug. 6, 2026 /PRNewswire/ -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) ("Hydreight" or the "Company"), a healthcare technology company operating a nationwide ph...
Victory Square Provides Update on Hydreight and Healthcare Investments Following FDA Advisory Committee Recommendations on Peptide-Related Bulk Drug Substances
VANCOUVER, BC, July 29, 2026 /PRNewswire/ -- Victory Square Technologies Inc. ("Victory Square", "VST" or the "Company") (CSE: VST) (OTCQX: VSQTF) (FWB: 6F6) is providing shareholders with an update f...
Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations
VANCOUVER, BC and LAS VEGAS, July 29, 2026 /PRNewswire/ -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (FSE: SO6) (OTCQB: HYDTF), a digital health platform connecting healt...
Hydreight Technologies Transcript: Planet MicroCap Las Vegas 2026
A multi-vertical healthcare platform reported record revenue growth, driven by compliance-focused expansion in direct-to-consumer virtual care and a robust nurse network. With strong cash reserves, operational leverage, and a growing suite of treatments, the company is positioned for continued scale and leadership in the telehealth market.
Hydreight Announces Refiling of Interim Financial Statements
VANCOUVER, BC and LAS VEGAS, June 2, 2026 /PRNewswire/ - Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a U.S.-focused digital health infrastructure...
Hydreight Technologies Earnings Call Transcript: Q1 2026
Record Q1 2026 revenue and profitability driven by broad-based growth and strong operating leverage. Regulatory tightening and rising consumer demand are accelerating platform adoption, supporting a reaffirmed full-year outlook of at least CAD 150 million in revenue.
Hydreight Technologies Earnings release: Q1 2026
Hydreight Technologies released its Q1 2026 earnings on June 2, 2026, summarizing the period's financial results.
Hydreight Technologies Report: Q1 2026
Hydreight Technologies published a report on June 2, 2026 containing material business information for investors and shareholders.
Hydreight Technologies MD&A: Q1 2026
Hydreight Technologies filed a regulatory document on June 2, 2026 disclosing important business information.
Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working Capital
Revenue increased 449% year-over-year while the Company continued to scale its healthcare infrastructure platform. VANCOUVER, BC and LAS VEGAS, June 1, 2026 /PRNewswire/ - Hydreight Technologies Inc. ...
Hydreight Technologies Announces Timing of Q1 2026 Financial Results and Investor Webcast
VANCOUVER, BC and LAS VEGAS, May 26, 2026 /PRNewswire/ - Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a rapidly growing digital health platform a...
Hydreight Technologies Earnings Call Transcript: Q4 2025
Revenue grew 121% year-over-year to CAD 35.4 million in 2025, driven by pharmacy sales and the VSDHOne platform. Adjusted EBITDA margin rose to 11% in Q4, and 2026 revenue guidance is set at a minimum of CAD 150 million.
Hydreight Technologies Earnings release: Q4 2025
Hydreight Technologies released its Q4 2025 earnings on May 1, 2026, summarizing the period's financial results.
Hydreight Technologies Report: Q4 2025
Hydreight Technologies published a report on May 1, 2026 containing material business information for investors and shareholders.
Hydreight Technologies MD&A: Q4 2025
Hydreight Technologies filed a regulatory document on May 1, 2026 disclosing important business information.
Hydreight Reports Record Fiscal 2025 Results as VSDHOne Drives Rapid Growth and Platform Scale
Achieves profitability, scales to 11,000+ platform licenses, and strengthens balance sheet with $15.7M in cash VANCOUVER, BC and LAS VEGAS, April 30, 2026 /PRNewswire/ - Hydreight Technologies Inc. (...